Japan Biosimilars Market Present Lots of Opportunities for Domestic Players, MP Advisors Report Available at MarketPublishers.com28 Aug 2017 • by Natalie Aster
LONDON – In 2016, encouraging uptake of Lantus biosimilars (BS) in Japan is illustrative of firm foothold of the marketer, product range targeted to diagnostic procedure combination hospitals and the early entry of the players are the factors boosting biosimilar penetration as well as market share dynamics of Japan’s biosimilar marketplace.
Whilst continuous discussion of domestic originator companies to launch authorised generic biosimilars in a way points out cost pressure and threat on the originator firms by payers, but put pause on attractiveness of developing biosimilars for a mid size and generic pharmaceutical companies. Small molecule authorised generic drugs launch in Japan (Aska’s Blopress, Nichi Iko’s) over the past few years grabbed the dominant (over 50%) market share amid generic players.
Worldwide, clear positive directions from the FDA to approve biosimilars in the USA, recent success of immune-oncology mAbs as an innovative treatment, and an increased use of these drugs in the Japanese market, greater confidence of Japanese prominent players for more biopharma success in the years to come versus small molecule will likely contribute to the market growth. These has enabled Japan’s diversified companies to venture in the world biologics CMO market space recently, and more M&A is anticipated this direction to fill the gap of biopharma-mAb technology platforms amid Japanese players.
Biosimilars present a lucrative opportunity of cumulative market size of close to USD 5.75 billion in the upcoming years for local biosimilar players.
New report “Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!” developed by MP Advisors assesses key forthcoming opportunity for the national BS market.
The study canvasses the competitive landscape, reviews the current trend of the use of biosimilars in Japan. It details Japanese ‘Chuikyo’ stand for biosimilar penetration and regulatory approval requirement for non-JP specific dosage strength or/has clinical findings from ex-Japan clinical research. The report discusses all the global and domestic players’ activities in the country’s biosimilar market space alongside their pipeline deal history, actual mAb tech platforms, alliances and deal structure. It gives an overview of the strategies of each of the 36 leading international and local players, their interest and focus on future cooperation in the biosimilar domain.
More new reports by the publisher can be found at MP Advisors page.